Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
January 05, 2022 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference 5 January 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a...
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases
December 12, 2021 09:01 ET
|
Silence Therapeutics plc
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and...
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
December 01, 2021 07:00 ET
|
Silence Therapeutics plc
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA)...
Silence Therapeutics Begins Exclusive Nasdaq Trading
November 30, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Begins Exclusive Nasdaq Trading 30 November 2021 LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and...
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 11, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
November 05, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
October 21, 2021 08:30 ET
|
Silence Therapeutics plc
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication...
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market
October 15, 2021 07:05 ET
|
Silence Therapeutics plc
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be...
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform
October 15, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform Hansoh will make a $16 million upfront cash payment and Silence has the...
Silence Therapeutics to Host R&D Day on October 21, 2021
October 07, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...